Inventera Wins FDA Approval for Phase 1 Trial of INV-003 Contrast Agent

• Inventera received FDA clearance on Oct. 16, 2026, for a Phase 1 trial of INV-003, its oral MRCP contrast agent.
• The US trial will enroll up to 30 adults to assess safety, tolerability and imaging efficacy.
• Completion is expected by Oct. 17, 2027, with results intended to establish the recommended Phase 2 dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventera Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261019900151), on October 19, 2026, and is solely responsible for the information contained therein.